Related Experiment Video
Updated: Aug 16, 2025
07:09
A Surgical Model of Heart Failure with Preserved Ejection Fraction in Tibetan Minipigs
Published on: February 18, 2022
2.0K
Medical Therapy for Heart Failure with Preserved Ejection Fraction
Sara Varnado1, Hyeon-Ju Ryoo Ali2, Barry Trachtenberg2,3
1Intermountain Medical Center, Murray, Utah, US.
Methodist Debakey Cardiovascular Journal
|December 23, 2022
Summary
New SGLT2 inhibitor medications offer improved outcomes for patients with heart failure with preserved ejection fraction (HFpEF). Research now focuses on better phenotyping to tailor HFpEF therapies for enhanced patient results.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Heart failure with preserved ejection fraction (HFpEF) presents diagnostic and etiological heterogeneity.
- Previous research focused on treatments for reduced ejection fraction, leading to numerous negative trials in HFpEF.
Purpose of the Study:
- To review recent advancements in treating HFpEF.
- To highlight the efficacy of SGLT2 inhibitors in improving outcomes for HFpEF patients.
Main Methods:
- Review of recent clinical trials and pharmacological studies on HFpEF treatments.
- Analysis of the impact of SGLT2 inhibitors on HFpEF patient outcomes.
Main Results:
- SGLT2 inhibitors have emerged as a beneficial treatment option for HFpEF.
- These medications have demonstrated significant improvements in patient outcomes.
Conclusions:
- SGLT2 inhibitors represent a breakthrough therapy for heart failure with preserved ejection fraction.
- Future research emphasis on improved patient phenotyping will enable more personalized HFpEF treatment strategies.
Related Concept Videos
01:30Heart Failure V: Medical Management
19
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
19
01:22Heart Failure VI: Adjunct Therapies
23
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
23
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
482
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
482
01:29Cardiomyopathy V: Interprofessional Care
25
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
25
01:22Heart Failure Drugs: Diuretics
445
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
445
01:30Cardiomyopathy II: Dilated Cardiomyopathy
19
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
19